NOVERA RETATRUTIDE: A NEW SOLUTION FOR BODY CONTROL?

New clinical evidence suggests that Novera Retatrutide, a dual-action treatment from Novo Nordisk, could provide a substantial step in body control. Differing from many existing drugs, Retatrutide targets both glucagon-like peptide-1 (GLP-1) and GIP, potentially resulting to improved decreases in